US5393192027 - Common Stock - After market: 0.85 +0.06 (+7.59%)
NASDAQ:LIXT (2/3/2023, 7:00:03 PM)+0.02 (+2.6%)
|GICS Sector||Health Care|
|Earnings (Last)||N/A N/A||Earnings (Next)||03-20 2023-03-20/bmo|
|Ins Owners||1%||Inst Owners||3.9%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
LIXTE BIOTECHNOLOGY HOLDINGS
No. 2, 248 Route 25A
East Setauket NEW YORK 11733
CEO: John S. Kovach
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on...
Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical...
Here you can normally see the latest stock twits on LIXT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.